ITEM 5.07 SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

On May 15, 2023, Nuvation Bio Inc. (the "Company") held its 2023 Annual Meeting of Stockholders (the "Annual Meeting") at which holders of 206,731,825 shares of the Company's common stock (consisting of 205,731,825 shares of Class A Common Stock and 1,000,000 shares of Class B Common Stock) were present in person or by proxy, representing 94% of the Company's Class A Common Stock and 100% of the Company's Class B Common Stock outstanding and entitled to vote as of the record date of March 17, 2023, and constituting a quorum for transaction of business. At the Annual Meeting, the Company's stockholders considered three proposals, each of which is described briefly below and in more detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 4, 2023 (the "Proxy Statement"). The final voting results for each proposal are set forth below.

Proposal No. 1 - Election of Directors.

The individuals listed below were elected at the Annual Meeting to serve as directors of the Company until the Company's 2026 annual meeting of stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal.



CLASS A STOCK DIRECTORS:          FOR        WITHHELD    BROKER NON-VOTE
Mr. Robert B. Bazemore, Jr.   140,642,378   50,106,962     14,982,485



CLASS B STOCK DIRECTORS:      FOR      WITHHELD   BROKER NON-VOTE
Kim Blickenstaff           1,000,000      0              0


Proposal No. 2 - Ratification of Independent Registered Public Accounting Firm.

The Company's stockholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.



    FOR       AGAINST   ABSTAIN   BROKER NON-VOTE
206,334,068   118,931   278,826          0

Proposal No. 3 - To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.

The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.



    FOR        AGAINST     ABSTAIN   BROKER NON-VOTE
153,714,329   38,025,124    9,887      14,982,485



                                       2

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses